MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, KNSA had -$17,985K decrease in cash & cash equivalents over the period. $136,417K in free cash flow.

Cash Flow Overview

Change in Cash
-$17,985K
Free Cash flow
$136,417K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from the maturities of ...
    • Proceeds from issuance of class ...
    • Accrued expenses, accrued collab...
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Inventory
    • Prepaid expenses and other curre...
    • Others

Cash Flow
2025-12-31
Net income (loss)
59,005
Depreciation and amortization expense
1,554
Share-based compensation expense
37,003
Non-cash lease expense
3,666
Net amortization (accretion) of discounts on short-term investments
916
Net (gain) loss on disposal of property and equipment
120
Deferred income taxes
13,002
Prepaid expenses and other current assets
22,481
Accounts receivable, net
-26,130
Inventory
28,531
Other long-term assets
1,210
Accounts payable
142
Accrued expenses, accrued collaboration expenses and other current liabilities
37,497
Operating lease liabilities
-3,455
Other long-term liabilities
16,699
Net cash provided by operating activities
137,985
Purchases of property and equipment
1,568
Purchases of short-term investments
386,915
Proceeds from the maturities of short-term investments
199,490
Net cash provided by (used in) investing activities
-188,993
Proceeds from issuance of class a ordinary shares under incentive award plans and employee share purchase plan
40,753
Payments in connection with ordinary stock tendered for employee tax obligations
7,730
Net cash provided by financing activities
33,023
Net increase (decrease) in cash and cash equivalents
-17,985
Cash and cash equivalents at beginning of period
183,581
Cash and cash equivalents at end of period
165,596
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net income (loss)$59,005K Accrued expenses,accrued collaboration...$37,497K Share-based compensationexpense$37,003K Accounts receivable, net-$26,130K Proceeds from issuance ofclass a ordinary...$40,753K Other long-termliabilities$16,699K Deferred income taxes$13,002K Non-cash lease expense$3,666K Depreciation andamortization expense$1,554K Accounts payable$142K Net cash provided byoperating activities$137,985K Net cash provided byfinancing activities$33,023K Canceled cashflow$56,713K Canceled cashflow$7,730K Net increase(decrease) in cash and cash...-$17,985K Canceled cashflow$171,008K Proceeds from thematurities of short-term...$199,490K Inventory$28,531K Prepaid expenses andother current assets$22,481K Operating leaseliabilities-$3,455K Other long-termassets$1,210K Net amortization(accretion) of discounts on...$916K Net (gain) loss ondisposal of property and...$120K Payments in connectionwith ordinary stock...$7,730K Net cash provided by(used in) investing...-$188,993K Canceled cashflow$199,490K Purchases of short-terminvestments$386,915K Purchases of property andequipment$1,568K

Kiniksa Pharmaceuticals International, plc (KNSA)

Kiniksa Pharmaceuticals International, plc (KNSA)